Advertisement

Skye Bioscience, Inc. SKYE

Set alert

Price alert · SKYE

All alert types
1.28 USD -0.02 -1.54%

At close · Oct 30

1.28 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
1.28 × 2
Ask
1.29 × 4
1.28 Day range 1.42
1.28 52-week range 12.40
YTD
-78.67%
1 year
-89.12%
Open
1.37
Prev close
1.30
Mkt cap
5.67M
Vol
40.56K
Avg vol
90.42K
EPS
-10.16
P/E
0.00
Div yield
0.00%
More statistics
Low
1.28
High
1.42
Forward P/E
-2.27
Beta
1.75
Short ratio
10.06
Inst. own
86.03%
Dividend
0.00
Ex-div date
Earnings
Mar 29, 2024
50-d avg
4.44
200-d avg
7.74
1y target
18.00

5m chart

Chart tools
Interval

Built from the cached five-day intraday bars.

Signals (52)
NameTimeAgo
MACD: Buy SignalOct 30, 9:35 AM2 days ago
SMA: BullishOct 30, 9:30 AM2 days ago
SMA: BearishOct 29, 3:45 PM3 days ago
RSI: OversoldOct 29, 3:45 PM3 days ago
SMA: BearishOct 29, 2:55 PM3 days ago
RSI: OversoldOct 29, 2:55 PM3 days ago
MACD: Sell SignalOct 29, 2:45 PM3 days ago
MACD: Buy SignalOct 29, 1:40 PM3 days ago
SMA: BullishOct 29, 1:35 PM3 days ago
SMA: BullishOct 29, 1:35 PM3 days ago
RSI: OversoldOct 29, 1:25 PM3 days ago
MACD: Sell SignalOct 29, 11:40 AM3 days ago
SMA: BullishOct 29, 10:20 AM3 days ago
SMA: BullishOct 29, 10:20 AM3 days ago
MACD: Buy SignalOct 29, 10:20 AM3 days ago
RSI: OversoldOct 29, 9:40 AM3 days ago
MACD: Sell SignalOct 28, 2:15 PM4 days ago
SMA: BearishOct 28, 2:05 PM4 days ago
MACD: Buy SignalOct 28, 1:25 PM4 days ago
SMA: BullishOct 28, 1:20 PM4 days ago
SMA: BullishOct 28, 1:20 PM4 days ago
SMA: BearishOct 28, 1:05 PM4 days ago
RSI: OversoldOct 28, 1:05 PM4 days ago
MACD: Sell SignalOct 28, 12:25 PM4 days ago
RSI: OverboughtOct 28, 11:35 AM4 days ago
SMA: BullishOct 28, 11:20 AM4 days ago
SMA: BearishOct 28, 10:20 AM4 days ago
SMA: BullishOct 28, 10:05 AM4 days ago
MACD: Buy SignalOct 28, 10:05 AM4 days ago
SMA: BearishOct 27, 3:55 PM5 days ago
MACD: Sell SignalOct 27, 3:55 PM5 days ago
RSI: OversoldOct 27, 3:55 PM5 days ago
SMA: BullishOct 27, 2:55 PM5 days ago
MACD: Buy SignalOct 27, 2:40 PM5 days ago
MACD: Sell SignalOct 27, 1:40 PM5 days ago
RSI: OversoldOct 27, 1:40 PM5 days ago
MACD: Buy SignalOct 27, 12:10 PM5 days ago
SMA: BullishOct 27, 12:00 PM5 days ago
SMA: BearishOct 27, 11:30 AM5 days ago
MACD: Sell SignalOct 27, 11:30 AM5 days ago
RSI: OversoldOct 27, 11:30 AM5 days ago
MACD: Buy SignalOct 27, 11:25 AM5 days ago
SMA: BearishOct 27, 10:20 AM5 days ago
RSI: OversoldOct 27, 10:20 AM5 days ago
MACD: Sell SignalOct 27, 10:00 AM5 days ago
SMA: BullishOct 26, 3:00 PM6 days ago
RSI: OverboughtOct 26, 3:00 PM6 days ago
MACD: Buy SignalOct 26, 2:00 PM6 days ago
MACD: Sell SignalOct 26, 12:55 PM6 days ago
SMA: BearishOct 26, 12:40 PM6 days ago
SMA: BullishOct 26, 12:25 PM6 days ago
RSI: OverboughtOct 26, 12:25 PM6 days ago

Key statistics

Market cap
79.79M
Enterprise value
14.69M
Trailing P/E
4.96
Forward P/E
-2.27
PEG ratio
0.00
Price / sales
0.00
Price / book
1.05
EPS (TTM)
0.53
Beta
1.75
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-15.71M
Total cash
67.41M
Total debt
190.99K
Return on equity
-54.82%
Shares outstanding
30.34M
Short % of float
7.83%
50-day average
4.44
200-day average
7.74

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 18.00 +1306.3% upside
Target (low)
14.00
Target (mean)
18.00
Target (high)
21.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Mar 29, 2024

Expected Mar 29, 2024. Consensus EPS estimate -0.285.

Earnings history

Financials — quick view

All financials
SKYE Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SKYE Net income — quarterly -10.79M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
SKYE EPS — quarterly -2.16
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

SKYE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.26-0.22+0.04+15.38%
Aug 9, 2024Jun 1, 2024-0.20-0.200.000.00%
May 10, 2024Mar 1, 2024-0.16-0.18-0.02-12.50%
Mar 29, 2024Dec 1, 2023-0.38———
Nov 13, 2023Sep 1, 20230.00-3.17——
Aug 7, 2023Jun 1, 20230.000.00——

Upgrades / downgrades

SKYE analyst upgrades and downgrades
DateFirmActionFromTo
Sep 30, 2024Scotiabankinit—Sector Outperform
Sep 20, 2024Piper SandlerreitOverweightOverweight
Sep 20, 2024Cantor FitzgeraldreitOverweightOverweight
Sep 10, 2024JMP Securitiesinit—Market Outperform
Sep 9, 2024Cantor FitzgeraldreitOverweightOverweight
Sep 6, 2024Cantor FitzgeraldreitOverweightOverweight

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SKYE — it syncs with the Stock Master app.

Insider holders

SKYE insider holders
InsiderRelationLatest transactionDateShares held
5AM PARTNERS VII, LLCBeneficial Owner of more than 10% of a Class of SecuritySaleSep 12, 20240
ARSENAULT KAITLYN MELANIEChief Financial OfficerSaleNov 17, 2024166,342
DHILLON PUNIT SChief Executive OfficerSaleNov 17, 2024339,166
DIEP TUAN TUOfficerSaleNov 17, 202482,259
EMERALD HEALTH SCIENCES, INC.Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Feb 21, 2023169,408,000
GRAYSON PAUL ADirectorSaleNov 17, 2024259,701

Institution ownership

SKYE institution ownership
Holder% heldSharesValueReported
5AM Venture Management, LLC35.32%9,913,16826.07MSep 29, 2024
Versant Venture Management, LLC7.15%2,007,7045.28MSep 29, 2024
Sphera Funds Management Ltd.5.57%1,563,5224.11MSep 29, 2024
Baker Bros. Advisors, LP5.11%1,434,6343.77MSep 29, 2024
Altium Capital Management, LP4.69%1,315,1463.46MSep 29, 2024
Blackrock Inc.4.25%1,193,5153.14MSep 29, 2024

Fund ownership

SKYE fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.70%477,1001.25MSep 29, 2024
iShares Russell 2000 ETF1.59%446,8141.18MOct 30, 2024
Vanguard Extended Market Index Fund0.89%249,751656.85KSep 29, 2024
Fidelity Small Cap Index Fund0.63%176,099463.14KAug 30, 2024
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF0.57%160,000420.80KOct 30, 2024
iShares Russell 2000 Value ETF0.49%136,819359.83KOct 30, 2024
Advertisement